CTI Clinical trials making cancer more treatable Making Cancer More Treatable
Cancer research products for clinical trials / Investigational Products / Clinical trials for sarcoma
CTI products for cancer research
sp
sp
Sarcoma
XYOTAX
Pixantrone cancer research drug for non-Hodgkin's lymphoma
Brostallicin cancer treatment for sarcoma
CT-2106
Clinical Studies
Clinical trials for lung cancer
Clinical trials for ovarian cancer
Clinical trial of brostallicin in soft tissue sarcoma
 

Sarcoma

Now enrolling for:

•

Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma
• Phase II, multicenter, open-label clinical trial designed to determine the efficacy and safety of brostallicin when administered once every 3 weeks in patients with myxoid liposarcoma with (12;16) translocation


Posted March 18, 2008

Copyright © 2004-2007 Cell Therapeutics, Inc., Seattle, WA, USA. All rights reserved. "Making cancer more treatable" is a registered mark of CTI.